C4 Therapeutics
CCCC
83 hedge funds and large institutions have $927M invested in C4 Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
25% more capital invested
Capital invested by funds: $743M → $927M (+$183M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11% more funds holding
Funds holding: 75 → 83 (+8)
5.43% more ownership
Funds ownership: 52.77% → 58.2% (+5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$43.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.6M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.7M |
| 5 |
Jennison Associates
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$4.75M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$4.62M |
CCCC Hedge Fund Activity: Q1 2021 in Review
83 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2021, worth a combined $927M — up 25% from $743M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CCCC positions and 10 closed out — a net gain of 8 holders — while 28 added to existing stakes and 21 trimmed.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $43.2M. The largest seller was Millennium Management, cutting an estimated $14.9M.
- 83 institutional investors held C4 Therapeutics (CCCC) as of Q1 2021, up from 75 in Q4 2020.
- Funds reported $927M of C4 Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
- 18 funds opened new C4 Therapeutics positions in Q1 2021 and 10 closed out, a net change of +8 holders.
- The largest C4 Therapeutics buyer in Q1 2021 was Wasatch Advisors, an estimated $43.2M added.
- The largest C4 Therapeutics seller in Q1 2021 was Millennium Management, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2021.